Journal of Neurochemistry · 2017 · 45 citations · 32 references
Life SciencesNeurobiologyNeuroscienceMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationDementia With Lewy BodiesIntracellular Calcium SignalingNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseProtein Aggregation DisordersAlpha-synuclein AggregationIntracellular Calcium HomeostasisNeuroblastoma BiologyProtein AggregatesProtein Aggregation In Neural TissueProtein Aggregation In NeuronsProtein Aggregation InhibitorsWestern Blot Analysis
Abstract Many neurodegenerative diseases are characterized by the formation of microscopically visible intracellular protein aggregates. α‐Synuclein is the key aggregating protein in Parkinson's disease which is characterized by neuronal cytoplasmic Lewy body inclusions. Previous studies have shown relative sparing of neurons in Parkinson's disease and dementia with Lewy bodies that are positive for the vitamin D‐dependent calcium‐buffering protein, calbindin‐D28k, and that α‐synuclein aggregates are excluded from calbindin‐D28k‐positive neurons. Recent cell culture studies have shown that α‐synuclein aggregation can be induced by raised intracellular‐free Ca( II ) and demonstrated that raised intracellular calcium and oxidative stress can act synergistically to promote α‐synuclein aggregation. We hypothesized that calcipotriol, a potent vitamin D analogue used pharmaceutically, may be able to suppress calcium‐dependent α‐synuclein aggregation by inducing calbindin‐D28k expression. Immunofluorescence and western blot analysis showed that calcipotriol potently induced calbindin‐D28k in a dose‐dependent manner in SH ‐ SY 5Y human neuroblastoma cells. Calcipotriol significantly decreased the frequency of α‐synuclein aggregate positive cells subjected to treatments that cause raised intracellular‐free Ca( II ) (potassium depolarization, KC l/H 2 O 2 combined treatment, and rotenone) in a dose‐dependent manner and increased viability. Suppression of calbindin‐D28k expression in calcipotriol‐treated cells using calbindin‐D28k‐specific si RNA showed significantly higher α‐synuclein aggregation levels, indicating that calcipotriol‐mediated blocking of calcium‐dependent α‐synuclein aggregation was dependent on the induction of calbindin‐D28k expression. These data indicate that targeting raised intraneuronal‐free Ca( II ) in the brain by promoting the expression of calbindin‐D28k at the transcriptional level using calcipotriol could prevent α‐synuclein aggregate formation and ameliorate Parkinson's disease pathogenesis. image
32
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Mihael H. Polymeropoulos, Christian Lavedan, Elisabeth Leroy et al. · Science · 1997 · 8.2K citations
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
J.J. Zarranz, Juan Carlos Gómez‐Esteban, Elena Lezcano et al. · Annals of Neurology · 2003 · 2.7K citations
Life Sciences, Genetics, Neurology +17
Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain
Darryl W. Eyles, Steven A. Smith, Robert Kinobe et al. · Journal of Chemical Neuroanatomy · 2004 · 1.4K citations
G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome
Suzanne Lesage, Mathieu Anheim, Franck Letournel et al. · Annals of Neurology · 2013 · 723 citations
Life Sciences, Genetics, Neurology +17